Cargando…

Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review

Despite their potential to prevent or delay the onset and progression of cardiovascular disease (CVD), medicines for CVD remain unavailable and unaffordable to many in low- and middle-income countries (LMICs). We systematically reviewed the literature to identify factors associated with availability...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotfizadeh, Ali, Palafox, Benjamin, Takallou, Armin, Balabanova, Dina, McKee, Martin, Murphy, Adrianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021589/
https://www.ncbi.nlm.nih.gov/pubmed/36962256
http://dx.doi.org/10.1371/journal.pgph.0000072
_version_ 1784908529171169280
author Lotfizadeh, Ali
Palafox, Benjamin
Takallou, Armin
Balabanova, Dina
McKee, Martin
Murphy, Adrianna
author_facet Lotfizadeh, Ali
Palafox, Benjamin
Takallou, Armin
Balabanova, Dina
McKee, Martin
Murphy, Adrianna
author_sort Lotfizadeh, Ali
collection PubMed
description Despite their potential to prevent or delay the onset and progression of cardiovascular disease (CVD), medicines for CVD remain unavailable and unaffordable to many in low- and middle-income countries (LMICs). We systematically reviewed the literature to identify factors associated with availability and affordability of CVD medicines in LMICs. A protocol for this study was registered on the PROSPERO register of systematic reviews (CRD42019135393). We searched Medline, EMBASE, Global Health, Cumulative Index to Nursing and Allied Health Literature, EconLit, Social Policy and Practice, and Africa Wide Information for studies analyzing factors associated with the presence of medicines (availability) or the price of these medicines as it relates to ability to pay (affordability) in LMICs. We performed a narrative synthesis of the results using an access to medicines framework that examines influences at different levels of the health system. We did not conduct a meta-analysis because of the differences in analytic approaches and outcome measures in different studies. The search was conducted in accordance with PRISMA guidelines. Of 43 studies meeting inclusion criteria, 41 were cross-sectional. Availability and affordability were defined and measured in different ways. A range of factors such as sociodemographic characteristics, facility tier, presence of medicines on national essential medicine lists, and international subsidy programs were examined. The studies had variable quality and findings were often inconsistent. We find gaps in the literature on factors associated with availability and affordability of CVD medicines, particularly at the health program level. We conclude that there is a need for experimental and quasi-experimental studies that could identify causal factors and effective responses. Such studies would help further our understanding of how complex multifactorial influences impact these outcomes, which could inform policy decisions. Along with this, greater standardization of definitions and measurement approaches of availability and affordability are needed to allow for more effective comparisons.
format Online
Article
Text
id pubmed-10021589
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100215892023-03-17 Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review Lotfizadeh, Ali Palafox, Benjamin Takallou, Armin Balabanova, Dina McKee, Martin Murphy, Adrianna PLOS Glob Public Health Research Article Despite their potential to prevent or delay the onset and progression of cardiovascular disease (CVD), medicines for CVD remain unavailable and unaffordable to many in low- and middle-income countries (LMICs). We systematically reviewed the literature to identify factors associated with availability and affordability of CVD medicines in LMICs. A protocol for this study was registered on the PROSPERO register of systematic reviews (CRD42019135393). We searched Medline, EMBASE, Global Health, Cumulative Index to Nursing and Allied Health Literature, EconLit, Social Policy and Practice, and Africa Wide Information for studies analyzing factors associated with the presence of medicines (availability) or the price of these medicines as it relates to ability to pay (affordability) in LMICs. We performed a narrative synthesis of the results using an access to medicines framework that examines influences at different levels of the health system. We did not conduct a meta-analysis because of the differences in analytic approaches and outcome measures in different studies. The search was conducted in accordance with PRISMA guidelines. Of 43 studies meeting inclusion criteria, 41 were cross-sectional. Availability and affordability were defined and measured in different ways. A range of factors such as sociodemographic characteristics, facility tier, presence of medicines on national essential medicine lists, and international subsidy programs were examined. The studies had variable quality and findings were often inconsistent. We find gaps in the literature on factors associated with availability and affordability of CVD medicines, particularly at the health program level. We conclude that there is a need for experimental and quasi-experimental studies that could identify causal factors and effective responses. Such studies would help further our understanding of how complex multifactorial influences impact these outcomes, which could inform policy decisions. Along with this, greater standardization of definitions and measurement approaches of availability and affordability are needed to allow for more effective comparisons. Public Library of Science 2022-03-23 /pmc/articles/PMC10021589/ /pubmed/36962256 http://dx.doi.org/10.1371/journal.pgph.0000072 Text en © 2022 Lotfizadeh et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lotfizadeh, Ali
Palafox, Benjamin
Takallou, Armin
Balabanova, Dina
McKee, Martin
Murphy, Adrianna
Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review
title Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review
title_full Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review
title_fullStr Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review
title_full_unstemmed Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review
title_short Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review
title_sort factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021589/
https://www.ncbi.nlm.nih.gov/pubmed/36962256
http://dx.doi.org/10.1371/journal.pgph.0000072
work_keys_str_mv AT lotfizadehali factorsassociatedwiththeavailabilityandaffordabilityofessentialcardiovasculardiseasemedicinesinlowandmiddleincomecountriesasystematicreview
AT palafoxbenjamin factorsassociatedwiththeavailabilityandaffordabilityofessentialcardiovasculardiseasemedicinesinlowandmiddleincomecountriesasystematicreview
AT takallouarmin factorsassociatedwiththeavailabilityandaffordabilityofessentialcardiovasculardiseasemedicinesinlowandmiddleincomecountriesasystematicreview
AT balabanovadina factorsassociatedwiththeavailabilityandaffordabilityofessentialcardiovasculardiseasemedicinesinlowandmiddleincomecountriesasystematicreview
AT mckeemartin factorsassociatedwiththeavailabilityandaffordabilityofessentialcardiovasculardiseasemedicinesinlowandmiddleincomecountriesasystematicreview
AT murphyadrianna factorsassociatedwiththeavailabilityandaffordabilityofessentialcardiovasculardiseasemedicinesinlowandmiddleincomecountriesasystematicreview